Moderna's triplet mRNA therapy treats checkpoint inhibitor-resistant tumors in mice

Moderna Inc. (NASDAQ:MRNA) published preclinical data Wednesday showing a triple mRNA combination product has efficacy against solid tumors, including those resistant to checkpoint inhibitors.

The company's mRNA-2752 contains mRNAs encoding IL-23, IL-36γ and OX40L encapsulated in a lipid nanoparticle. Moderna is testing mRNA-2752 as monotherapy or in combination with Imfinzi durvalumab or tremelimumab from AstraZeneca plc (LSE:AZN; NYSE:AZN) in a Phase I trial to treat advanced or metastatic solid tumor malignancies or lymphoma...